# Helen Liang

> Helen Liang is a seed investor at FoundersX Ventures backing Artificial Intelligence and Software. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [FoundersX Ventures](https://shizune.co/investors/profile/foundersx-ventures)
- Location: Menlo Park, United States
- Total investments: 15
- Last investment: Sep 2025
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/helen11390/
- X (Twitter): https://twitter.com/HelenSandHill
- Website: https://x.com/HelenSandHill

Helen Liang is a seed investor at FoundersX Ventures in Menlo Park focused on Artificial Intelligence and Software. Founder & Managing Partner of FoundersX Ventures, a Silicon Valley based AI-first venture capital firm with strong focus on building Agentic AI powered tech infrastructure and disruptive solutions across industries, from enterprise, Finance, to Digital health solutions. Over 10 years of product and operation experience in high-tech industry.Backed over 100 startup founders. Featured on WSJ and Business Insider as a pioneering tech VC. Board director. Guest lecturer at Stanford. Invited speaker at TechCrunch.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 6 | 40% |
| Software | 4 | 27% |
| FinTech | 3 | 20% |
| Information Technology | 3 | 20% |
| Therapeutics | 2 | 13% |

39 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 67% |
| Series A | 2 | 13% |
| Series B | 2 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 60% |
| Mexico | 2 | 13% |
| United Kingdom | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kontigo | We help underbanked gig workers in Latam build credit and access group financing where small groups of family or friends lend and save money together. Users can validate their income from multiple sources such as gig apps, catalog sales, and open finance (Uber, Rappi, Didi, Indriver, Avon, and all major banks). After verifying the income wedirectly offer them group savings and group loans, without leaving WhatsApp, their primary messaging app. | $20M | Seed | Sep 01, 2025 |  |
| Mbodi AI | Teach robots new skills through natural language and run reliably in production in minutes. Mbodi combines generative AI, agent orchestration, and symbolic reasoning, turning everyday language and quick demos into precise, reliable robot actions for industrial automation. |  | Seed | Jun 02, 2025 |  |
| FS2 Business | FS2 Business is a technology company. | $2.6M | Seed | Jan 22, 2025 |  |
| Kapital | Kapital empowers SMBs with a tech-banking platform giving visibility and control of their treasury, and their employees | $24M | Series A | May 25, 2023 |  |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies designed to treat neurodegenerative diseases by stimulating specific brain activity patterns. The company focuses on noninvasive therapeutic systems that use synchronized visual and auditory stimulation to influence neural activity associated with cognitive function and brain health. Itstechnology platform, Spectris, is designed to evoke gamma-frequency brain waves, which play a role in learning, memory, and communication between neurons. The platform delivers controlled light and sound signals through a wearable device to trigger gamma oscillations in the brain, a pattern of neural activity that is disrupted in conditions such as Alzheimer’s disease. By restoring this activity, the therapy aims to support processes related to synaptic function, myelin integrity, and neural connectivity.Cognito Therapeutics conducts clinical research and trials to evaluate how its neuromodulation technology affects cognitive performance, brain structure, and functional abilities in patients with neurodegenerative disorders. The company studies the biological effects of sensory stimulation on brain pathways, immune responses, and neural signaling networks associated with disease progression. Through its research programs and device development, Cognito Therapeutics produces medical technologies intended for clinical treatment and investigation of neurological conditions that affect memory, cognition, and daily functioning. | $73M | Series B | Mar 22, 2023 |  |
| Devyce | Devyce creates a VoIP operating system that offers communication system with flexibility, scalability, and dependability. The company was founded by Leo Bartle, Nicholas Browne, and Edward Clayton in 2020 and is headquartered in London, England, United Kingdom. | $4.2M | Seed | Feb 28, 2023 |  |
| ContaLink | Automation and Customer Engagement Software for Accountants in Mexico. | $2.2M | Seed | Mar 15, 2022 |  |
| Nitra | Nitra offers expense management software that integrates with the banks to provide innovative loan products. |  | Seed | Jan 20, 2022 |  |
| Kapital | Kapital empowers SMBs with a tech-banking platform giving visibility and control of their treasury, and their employees | $20M | Series A | Jan 05, 2022 |  |
| Menten AI | Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning andquantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications. | $3.7M | Seed | Jun 30, 2020 |  |

10 of 15 investments shown.

## Co-investors
- [Y Combinator](https://shizune.co/investors/profile/y-combinator) — VC Fund, 5 deals together
- [Pioneer Fund](https://shizune.co/investors/profile/pioneer-fund) — VC Fund, 4 deals together
- [Scribble Ventures](https://shizune.co/investors/profile/scribble-ventures) — VC Fund, 3 deals together
- [Broom Ventures](https://shizune.co/investors/profile/fathom-ventures) — VC Fund, 2 deals together
- [FoundersX Ventures](https://shizune.co/investors/profile/foundersx-ventures) — VC Fund, 2 deals together
- [Marbruck](https://shizune.co/investors/profile/marbruck) — VC Fund, 2 deals together

## About FoundersX Ventures

VC Fund · Menlo Park, United States

Established in 2016 and based in Silicon Valley, FoundersX is a deep-domain winner with investment focus on deep tech, enterprise AI and digital infrastructure. We outcompete with our deep-dive research capacity. We are an early investor in multiple tech unicorns with several home runs, and have over 20 high growth companies valued at over $100M.We have highly competitive deal flows and high hit rate. Our firm is featured on the WSJ and Business Insider as a pioneering tech VC.

5 contacts available at FoundersX Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Helen Liang | Founder & Managing Partner | https://shizune.co/investors/profile/helen-liang |
| Kevin Shey | Venture Partner | https://shizune.co/investors/profile/kevin-shey |
| Benjamin Xu | Partner | https://shizune.co/investors/profile/benjiamin-xu |
| Tom Kosnik | Partner | https://shizune.co/investors/profile/tom-kosnik |
| Tom Kosnik | Partner | https://shizune.co/investors/profile/tom-kosnik-6ef6 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Helen Liang invest in?

Helen Liang invests primarily in Artificial Intelligence, Software and FinTech startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Helen Liang last invest?

The most recent investment recorded for Helen Liang closed in Sep 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co